April 17-22, 2026, American Association for Cancer Research
1) Exceptionally selective and orally bioavailable p300 degraders for the treatment of CBP-mutant and p300-dependent cancers 2) Discovery and characterization of once in a month intravenous and orally bioavailable SMARCA2 degraders for
April 13- 16, 2026, Drug Discovery Chemistry
1) Novel Macrocyclic KIF18A Inhibitors for Treatment of Chromosomally Unstable Tumors: Discovery and Preclinical Characterization 2) Discovery and Optimization of a First-in-Class p300-Selective Oral Degrader Candidate
October 22-26, 2025, AACR-NCI-EORTC International-Conference
1)Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers. 2)Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis
April 25-30, 2025, American Association for Cancer Research
1)Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers. 2)Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis
September 30- October 3, 2024, Discovery on Target
1) Discovery and Development of pan-KRAS Degraders for Cancer Therapyn 2) Efficacy of a First-in-Class Polymerase Theta Degrader in Preclinical Cancer Models
September 1-5, 2024, XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024)
1) Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072) April 5- 10, 2024, AACR Conference
1) SMARCA 2/4 Degraders Relieve The Differentiation Block In AML via Changes In Chromatin Looping and Accessibility2) Paralogue Selectivity p300 Degraders Induce Synthetic Lethality in Pre-Clinical Models of CBP- Deficient